Kineta Announces Promising New Data For KIN 1148 – A Novel Vaccine Adjuvant For Highly Pathogenic Flu

SEATTLE--(BUSINESS WIRE)--Kineta, Inc., a biotechnology company focused on the translational development of novel antiviral and immune modulating drugs, announced promising new data demonstrating that KIN 1148 enhances the efficacy of existing influenza vaccines in animal models through a balanced immune response. Additionally, enhanced effectiveness with KIN 1148 was achieved while using lower vaccine doses. Kineta’s vaccine adjuvants are small molecule compounds added to a vaccine to improve the body’s vaccine immune response. The data were presented by Dr. Kristin Bedard, Kineta’s Vice President of Research and Development, during a presentation at the 16^th Annual World Vaccine Congress in Washington, DC.

“It provides a >15-fold dose sparing effect which can maximize the crucial supply of influenza split vaccines.”

“KIN 1148 is a novel vaccine adjuvant that targets IRF-3 innate immune pathways with the potential to induce a protective immune response, boost neutralizing antibodies and reduce inflammation,” Dr. Bedard stated. “It provides a >15-fold dose sparing effect which can maximize the crucial supply of influenza split vaccines.”

About KIN 1148 – Vaccine Adjuvant System

Kineta’s vaccine development group has identified novel immune modulating adjuvants that enhance the efficacy of existing vaccines through a balanced immune response while using lower vaccine doses. KIN 1148 is the lead compound that is in preclinical development. It was discovered through Kineta’s proprietary AViid™ discovery platform which is focused on screening for small molecules that activate IRF-3 dependent innate immune pathways. KIN 1148 provides a targeted approach that safely stimulates innate immune protective pathways. This program is conducted in collaboration with the National Institutes of Health (NIH) and University of Washington.

Kineta, Inc. is an emerging and sustainable biotech company that fills a void in the biopharmaceutical industry by efficiently advancing therapies from discovery to clinical proof of concept. We actively collaborate with a broad array of private, government and industry partners to advance our innovative research in autoimmune diseases, antivirals and chronic pain. Kineta has established and is expanding on a diverse pipeline of novel life improving therapies that address critical unmet patient needs. For more information on Kineta, Inc., visit our website, www.Kinetabio.com.

NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Kineta’s plans for pre-clinical and clinical studies, regulatory filings, and anticipated drug effects in human subjects. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta’s business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and Kineta undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.